Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/8/2019
SIETES contiene 92796 citas

 
 
 1 a 20 de 40 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Egilman AC, Zhang AD, Wallach JD, Ross JS. Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors . Ann Intern Med 2019:1. [Ref.ID 103162]
2. Cita con resumen
Voelker R. New pancreatic cancer drug. JAMA 2015;314:2227. [Ref.ID 99728]
3. Cita con resumen
Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014;383:1490-502. [Ref.ID 97540]
4. Cita con resumen
Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH, Pockaj BA, Grothey A, Goldberg RM. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer. A randomized trial. JAMA 2012;307:1383-93. [Ref.ID 92698]
5. Cita con resumen
Anónimo. Glucarpidase (Voraxaze) for methotrexate toxicity. Med Lett Drugs Ther 2012;54:19-20. [Ref.ID 92503]
6. Cita con resumen
Gatesman ML, Smith TJ. The shortage of essential chemotherapy drugs in the United States. N Engl J Med 2011;365:1653-5. [Ref.ID 91589]
7. Cita con resumen
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul J-L, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet J-B, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, for the Groupe Tumeurs Digestives of Unicancer and the PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25. [Ref.ID 90618]
8. Cita con resumen
Howard DH, Kauh J, Lipscomb J. The value of new chemotherapeutic agents for metastatic colorectal cancer. Arch Intern Med 2010;170:537-42. [Ref.ID 88194]
9. Cita con resumen
Bendell J. Optimum chemotherapy for metastatic colorectal cancer. Lancet 2006;368:2039-41. [Ref.ID 78655]
10.
Glimelius B. Benefit-risk assessment of irinotecan in advanced colorectal cancer. Drug Saf 2005;28:417-33. [Ref.ID 73938]
11. Cita con resumen
Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet 2005;365:153-65. [Ref.ID 72482]
12.Tiene citas relacionadas
Erlichman C, Sargent DJ. New treatment options for colorectal cancer. N Engl J Med 2004;351:391-2. [Ref.ID 70874]
13.Tiene citas relacionadas Cita con resumen
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45. [Ref.ID 70872]
14.Tiene citas relacionadas Cita con resumen
Schrag D. The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 2004;351:317-22. [Ref.ID 70870]
15.Tiene citas relacionadas
Mayer RJ. Two steps forward in the treatment of colorectal cancer. N Engl J Med 2004;350:2406. [Ref.ID 70209]
16.Tiene citas relacionadas
Pfister D G, Benson III AB, Somerfield MR. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med 2004;350:2375-82. [Ref.ID 70208]
17.Tiene citas relacionadas
André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, for the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51. [Ref.ID 70207]
18.Tiene citas relacionadas Cita con resumen
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Haisnworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42. [Ref.ID 70206]
19. Cita con resumen
Otten HM, Mathijssen J, Ten Cate H, Soesan M, Inghels M, Richel D J, Prins M H. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy. An underestimated phenomenon. Arch Intern Med 2004;164:190-4. [Ref.ID 68874]
20.Tiene citas relacionadas Cita con resumen
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003;361:1927-34. [Ref.ID 66167]
Seleccionar todas
 
 1 a 20 de 40 siguiente >>